Clinical trial spots for cancer patients by tumour type: The cancer trials portfolio at clinicaltrials.gov

Vinay Prasad, Jeffery A. Goldstein

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Background Although participation in cancer clinical trials is low, little is known about the number of available clinical trials, and open spots for patients. Moreover, it is unclear what the relationship is between clinical trial openings and the incidence and mortality of cancer subtypes. Methodology We identified the number of phase I, phase II and phase III registered at clinicaltrials.gov by cancer (tumour) type. All counts were over the preceding 5 years (2008-2013). We compared these counts against the incidence and prevalence of disease reported by Surveillance, Epidemiology and End Results (SEER) database for 32 common cancers. Results From 2008 to 2013, 3879 phase I trials, 4982 phase II trials and 1379 phase III trials concerning a cancer subtype were registered in clinicaltrials.gov. These trials had a cumulative proposed recruitment of 203,396, 421,502 and 697,787 patients, respectively. Trial enrolment varied by tumour type, with both over and under-representation occurring. Conclusion Opportunities to enrol in clinical trials vary by phase and tumour type. Oncologists must remain committed to clinical trials.

Original languageEnglish (US)
Pages (from-to)2718-2723
Number of pages6
JournalEuropean Journal of Cancer
Volume51
Issue number17
DOIs
StatePublished - 2015
Externally publishedYes

Fingerprint

Clinical Trials
Neoplasms
Incidence
Epidemiology
Databases
Mortality

Keywords

  • Burden of disease
  • Cancer clinical trials
  • Cancer trials
  • Cancer trials portfolio
  • Clinicaltrials.gov
  • Phase I, phase II and phase III

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Clinical trial spots for cancer patients by tumour type : The cancer trials portfolio at clinicaltrials.gov. / Prasad, Vinay; Goldstein, Jeffery A.

In: European Journal of Cancer, Vol. 51, No. 17, 2015, p. 2718-2723.

Research output: Contribution to journalArticle

@article{dfee18207daf44adbb0d8a3908420f04,
title = "Clinical trial spots for cancer patients by tumour type: The cancer trials portfolio at clinicaltrials.gov",
abstract = "Background Although participation in cancer clinical trials is low, little is known about the number of available clinical trials, and open spots for patients. Moreover, it is unclear what the relationship is between clinical trial openings and the incidence and mortality of cancer subtypes. Methodology We identified the number of phase I, phase II and phase III registered at clinicaltrials.gov by cancer (tumour) type. All counts were over the preceding 5 years (2008-2013). We compared these counts against the incidence and prevalence of disease reported by Surveillance, Epidemiology and End Results (SEER) database for 32 common cancers. Results From 2008 to 2013, 3879 phase I trials, 4982 phase II trials and 1379 phase III trials concerning a cancer subtype were registered in clinicaltrials.gov. These trials had a cumulative proposed recruitment of 203,396, 421,502 and 697,787 patients, respectively. Trial enrolment varied by tumour type, with both over and under-representation occurring. Conclusion Opportunities to enrol in clinical trials vary by phase and tumour type. Oncologists must remain committed to clinical trials.",
keywords = "Burden of disease, Cancer clinical trials, Cancer trials, Cancer trials portfolio, Clinicaltrials.gov, Phase I, phase II and phase III",
author = "Vinay Prasad and Goldstein, {Jeffery A.}",
year = "2015",
doi = "10.1016/j.ejca.2015.07.045",
language = "English (US)",
volume = "51",
pages = "2718--2723",
journal = "European Journal of Cancer",
issn = "0959-8049",
publisher = "Elsevier Limited",
number = "17",

}

TY - JOUR

T1 - Clinical trial spots for cancer patients by tumour type

T2 - The cancer trials portfolio at clinicaltrials.gov

AU - Prasad, Vinay

AU - Goldstein, Jeffery A.

PY - 2015

Y1 - 2015

N2 - Background Although participation in cancer clinical trials is low, little is known about the number of available clinical trials, and open spots for patients. Moreover, it is unclear what the relationship is between clinical trial openings and the incidence and mortality of cancer subtypes. Methodology We identified the number of phase I, phase II and phase III registered at clinicaltrials.gov by cancer (tumour) type. All counts were over the preceding 5 years (2008-2013). We compared these counts against the incidence and prevalence of disease reported by Surveillance, Epidemiology and End Results (SEER) database for 32 common cancers. Results From 2008 to 2013, 3879 phase I trials, 4982 phase II trials and 1379 phase III trials concerning a cancer subtype were registered in clinicaltrials.gov. These trials had a cumulative proposed recruitment of 203,396, 421,502 and 697,787 patients, respectively. Trial enrolment varied by tumour type, with both over and under-representation occurring. Conclusion Opportunities to enrol in clinical trials vary by phase and tumour type. Oncologists must remain committed to clinical trials.

AB - Background Although participation in cancer clinical trials is low, little is known about the number of available clinical trials, and open spots for patients. Moreover, it is unclear what the relationship is between clinical trial openings and the incidence and mortality of cancer subtypes. Methodology We identified the number of phase I, phase II and phase III registered at clinicaltrials.gov by cancer (tumour) type. All counts were over the preceding 5 years (2008-2013). We compared these counts against the incidence and prevalence of disease reported by Surveillance, Epidemiology and End Results (SEER) database for 32 common cancers. Results From 2008 to 2013, 3879 phase I trials, 4982 phase II trials and 1379 phase III trials concerning a cancer subtype were registered in clinicaltrials.gov. These trials had a cumulative proposed recruitment of 203,396, 421,502 and 697,787 patients, respectively. Trial enrolment varied by tumour type, with both over and under-representation occurring. Conclusion Opportunities to enrol in clinical trials vary by phase and tumour type. Oncologists must remain committed to clinical trials.

KW - Burden of disease

KW - Cancer clinical trials

KW - Cancer trials

KW - Cancer trials portfolio

KW - Clinicaltrials.gov

KW - Phase I, phase II and phase III

UR - http://www.scopus.com/inward/record.url?scp=84969833441&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84969833441&partnerID=8YFLogxK

U2 - 10.1016/j.ejca.2015.07.045

DO - 10.1016/j.ejca.2015.07.045

M3 - Article

C2 - 26321010

AN - SCOPUS:84969833441

VL - 51

SP - 2718

EP - 2723

JO - European Journal of Cancer

JF - European Journal of Cancer

SN - 0959-8049

IS - 17

ER -